

CLAIMS

1. A method for the production of an antiangiogenic and/or vascular permeability
reducing effect in a warm-blooded animal such as a human, which comprises administering to
5 said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof,
before, after or simultaneously with an effective amount of ZD1839 or a pharmaceutically
acceptable salt thereof.

2. A method for the production of an antiangiogenic and/or vascular permeability
10 reducing effect in a warm-blooded animal such as a human, which comprises administering to
said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof,
before, after or simultaneously with an effective amount of ZD1839 or a pharmaceutically
acceptable salt thereof and before, after or simultaneously with an effective amount of ionising
radiation.

15

3. A method for the treatment of a cancer in a warm-blooded animal such as a human,
which comprises administering to said animal an effective amount of ZD6474 or a
pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective
amount of ZD1839 or a pharmaceutically acceptable salt thereof.

20

4. A method for the treatment of a cancer in a warm-blooded animal such as a human,
which comprises administering to said animal an effective amount of ZD6474 or a
pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective
amount of ZD1839 or a pharmaceutically acceptable salt thereof and before, after or
25 simultaneously with an effective amount of ionising radiation.

5. A method for the treatment of a cancer involving a solid tumour in a warm-blooded
animal such as a human, which comprises administering to said animal an effective amount of
ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an
30 effective amount of ZD1839 or a pharmaceutically acceptable salt thereof.

6. A method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of ZD6474 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of ZD1839 or a pharmaceutically acceptable salt thereof and before, after or
5 simultaneously with an effective amount of ionising radiation.

7. A pharmaceutical composition which comprises ZD6474 or a pharmaceutically acceptable salt thereof, and ZD1839 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.

10

8. A kit comprising ZD6474 or a pharmaceutically acceptable salt thereof, and ZD1839 or a pharmaceutically acceptable salt thereof.

9. Use of ZD6474 or a pharmaceutically acceptable salt thereof and ZD1839 or a
15 pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human.

10. Use of ZD6474 or a pharmaceutically acceptable salt thereof and ZD1839 or a
20 pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is being treated with ionising radiation.

11. Use of ZD6474 or a pharmaceutically acceptable salt thereof and ZD1839 or a
25 pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human.

12. Use of ZD6474 or a pharmaceutically acceptable salt thereof and ZD1839 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the
30 production of an anti-cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation.

13. Use of ZD6474 or a pharmaceutically acceptable salt thereof and ZD1839 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-tumour effect in a warm-blooded animal such as a human.

- 5 14. Use of ZD6474 or a pharmaceutically acceptable salt thereof and ZD1839 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the production of an anti-tumour effect in a warm-blooded animal such as a human which is being treated with ionising radiation.